top of page
Science Lab

TACC-3

Coiled Therapeutics, a drug development company based in the US is a clinical stage oncology company. Our AI-driven molecule discovery has led to clinical trials for a TACC3 protein-targeting drug for triple-negative breast, ovarian and other cancers.

Abstract Linear Background

Experienced Professionals

At Coiled Pharmaceuticals, our mission is to leverage the experience of our team to help cancer patients

About

Pitch Deck

Blue Light

Pipeline

Blue Light
Abstract Linear Background

TACC3-Targeting Drug

Our TACC3 protein-protein interaction targeted new drug candidate AO-252 is currently undergoing clinical trials for triple-negative breast, ovarian and endomertrial cancers. Complete regressions and no significant toxicity in pre-clinical animal models give us confidence in introducing this novel approach to treating cancer patients.

Abstract Linear Background

Innovative Research

Our research team is dedicated to developing the latest advancements in cancer treatment. Our AI-driven target and molecule design platform has led to a potentially groundbreaking TACC3 program.

Pharmacist Checking Medicine
Abstract Linear Background
Sorting Medicine
Abstract Linear Background

Clinical Trials

Our TACC3-protein targeting drug is currently undergoing clinical trials for triple-negative breast, ovarian and endometrial cancers at multiple hospitals.

bottom of page